ESTRELLA IMMUNOPHARMA, INC. Deferred Income Tax Liabilities, Net
ESTRELLA IMMUNOPHARMA, INC. (ESLA) had Deferred Income Tax Liabilities, Net of $8.37 thousand as of 2023-06-30, per its 10-Q filed 2023-08-01.
Discontinued › Balance Sheet › Liabilities › Liabilities, Other than Long-Term Debt, Noncurrent
us-gaap:DeferredIncomeTaxLiabilitiesNet · last filed 2023-08-01
- 2023-06-30: Deferred Income Tax Liabilities, Net $8.37K.
- 2023-03-31: Deferred Income Tax Liabilities, Net $7.77K.
- 2022-12-31: Deferred Income Tax Liabilities, Net $29.47K.
| Period end | Deferred Income Tax Liabilities, Net |
|---|---|
| 2023-06-30 | $8.37K 10-Q · filed 2023-08-01 |
| 2023-03-31 | $7.77K 10-Q · filed 2023-05-18 |
| 2022-12-31 | $29.47K 10-Q · filed 2023-08-01 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Jasper Therapeutics, Inc. (JSPR) | United States | $0.020B | -0.37 |
| BioCardia, Inc. (BCDA) | United States | $0.016B | |
| DYADIC INTERNATIONAL INC (DYAI) | United States | $0.016B | |
| Passage BIO, Inc. (PASG) | United States | $0.015B | -0.43 |
| Pluri Inc. (PLUR) | $0.014B | ||
| INTENSITY THERAPEUTICS, INC. (INTS) | United States | $0.013B | -1.08 |
| BRAINSTORM CELL THERAPEUTICS INC. (BCLI) | United States | $0.013B | -1.05 |
| IN8BIO, INC. (INAB) | United States | $0.012B | -0.76 |
| Senti Biosciences Holdings, Inc. (SNTI) | United States | $0.011B | -0.70 |
| CEL SCI CORP (CVM) | United States | $0.030B | -0.81 |